

## Chordate CEO Anders Weilandt explains study results at Aktiedagen on September 12th

**On Monday, September 12th, 11:00, Chordate's CEO Anders Weilandt will participate on Aktiespararnas event Aktiedagen Stockholm. He will mainly talk about the subgroup result of the migraine study PM007 on the K.O.S treatment that was presented in London on September 8, and what it means for the company. The subgroup result shows a statistically significant reduction in the number of headache days.**

"This event will be a good opportunity for me to explain the very positive result from the subgroup analysis, how it should be interpreted and what it means for the company going forward", says Anders Weilandt, Chordate CEO.

Aktiedagen takes place at Hotel Birger Jarl in Stockholm. To attend on site, [register here](#). The event is streamed live at [www.aktiespararna.se/tv/live](http://www.aktiespararna.se/tv/live) and on Aktiespararna's [Youtube channel](#). No registration is required to follow the event digitally.

After the presentation, Anders Weilandt will participate in a Q&A and questions can be asked by sending an SMS to +46 79-347 98 45 or an email to [event@aktiespararna.se](mailto:event@aktiespararna.se). Questions can be sent in now or during the presentation.

**For more information, please contact:**

Anders Weilandt, CEO  
[anders.weilandt@chordate.com](mailto:anders.weilandt@chordate.com)  
Cell: +46 733-874277

**About Chordate**

Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in the Nordics, Germany, the UK, Israel, and Saudi Arabia. Chordate Medical's share is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at [www.chordate.com/en/](http://www.chordate.com/en/)

Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB, +46 40 200 250, [ca@vhcorp.se](mailto:ca@vhcorp.se).

*N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.*

Press Release  
08 September 2022 15:00:00 CEST

**CHORDATE**  
M E D I C A L

---

**Attachments**

[Chordate CEO Anders Weilandt explains study results at Aktiedagen on September 12th](#)